Of cats and men: Immunodominance and the role of HLA-DP/DQ

Clinical and Experimental Allergy

Volumn 38, Issue 11, 2008, Pages 1709-1711

  Larche M ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; EPITOPE; FEL D 1 ALLERGEN; GAMMA INTERFERON; HLA DP ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 4; RECOMBINANT ALLERGEN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN RECOGNITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; EDITORIAL; EPITOPE MAPPING; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY;

ANIMALS; CATS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DERMATITIS, ATOPIC; DESENSITIZATION, IMMUNOLOGIC; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; GLYCOPROTEINS; HLA-DP ANTIGENS; HLA-DQ ANTIGENS; HUMANS; HYPERSENSITIVITY; IMMUNODOMINANT EPITOPES; MEMBRANE GLYCOPROTEINS;

EID: 54849436659     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2008.03112.x     Document Type: Editorial

References (26)

1. Valenta R, Lidholm J, Niederberger V, Hayek B, Kraft D, Gronlund H. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy 1999 29 : 896 904.
2. Hiller R, Laffer S, Harwanegg C et al. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J 2002 16 : 414 6.
3. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002 109 : 251 6.
4. Polosa R, Al-Delaimy WK, Russo C, Piccillo G, Sarva M. Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir Res 2005 6 : 1 11.
5. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001 31 : 1392 7.
6. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006 6 : 761 71.
7. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005 116 : 608 13.
8. Arquint O, Helbling A, Crameri R, Ferreira F, Breitenbach M, Pichler WJ. Reduced in vivo allergenicity of Bet v 1d isoform, a natural component of birch pollen. J Allergy Clin Immunol 1999 104 : 1239 43.
9. Valenta R, Kraft D. From allergen structure to new forms of allergen-specific immunotherapy. Curr Opin Immunol 2002 14 : 718 27.
10. Gafvelin G, Thunberg S, Kronqvist M et al. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 2005 138 : 59 66.
11. Niederberger V, Horak F, Vrtala S et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004 101 (Suppl. 2) : 14677 82.
12. Reisinger J, Horak F, Pauli G et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 2005 116 : 347 54.
13. Tulic MK, Fiset PO, Christodoulopoulos P et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004 113 : 235 41.
14. Creticos PS, Schroeder JT, Hamilton RG et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006 355 : 1445 55.
15. Kundig TM, Senti G, Schnetzler G et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006 117 : 1470 6.
16. Alexander C, Tarzi M, Larche M, Kay AB. The effect of Fel d 1-derived T cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005 60 : 1269 74.
17. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002 360 : 47 53.
18. Tarzi M, Klunker S, Texier C et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006 36 : 465 74.
19. Alexander C, Ying S, Kay B, Larche M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4CD25; CD4 interferon-gamma T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy 2005 35 : 52 8.
20. Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005 11 : S69 76.
21. del Guercio MF, Alexander J, Kubo RT et al. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 1997 15 : 441 8.
22. Haselden BM, Kay AB, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999 189 : 1885 94.
23. Castelli FA, Buhot C, Sanson A et al. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J Immunol 2002 169 : 6928 34.
24. Bateman EAL, Ardern-Jones MR, Ogg GST. Identification of an immunodominant region of Fel d 1 and characterization of constituent epitopes. Clin Exp Allergy 2008 38 : 1760 8.
25. Akdis M, Verhagen J, Taylor A et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004 199 : 1567 75.
26. Arif S, Tree TI, Astill TP et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004 113 : 451 63.